Reveleer Launches Next Generation Risk Solution for Unparalleled Accuracy, Efficiency, and Financial Performance

New AI-driven technology transforms retrospective risk adjustment with real-time insights enhancing coding precision and automated workflows
GLENDALE, Calif., March 5, 2025 /PRNewswire/ -- Reveleer, the leading value-based care enablement platform, today announced the launch of its next generation retrospective risk technology, designed to advance risk adjustment programs with unparalleled accuracy, efficiency, and compliance.
As payers and providers navigate increasingly complex regulatory environments, accurate risk adjustment has never been more critical. Reveleer's advanced technology ensures precise Medical Record Review (MRR) while improving operational and financial impact without compromising compliance. By harnessing the power of AI with EVE (Reveleer's Evidence Validation Engine), Reveleer now leads the market through its predictive clinical insights with up to 99% accuracy, advanced dynamic clinical validation, and intelligent automation that reduces coding duration by up to 42.5%. Combined with a modern user experience, Reveleer is transforming retrospective risk with remarkable accuracy, productivity and financial performance for its customers.
'Our platform is built for those seeking to modernize their risk adjustment programs with artificial intelligence assisted workflows,' said Paul Burke, Chief Product Officer at Reveleer. 'By leveraging our proprietary technology and intelligent automation, we provide our customers with the opportunity to increase their efficiency and productivity while improving their RAF accuracy and HCC capture.'
Key benefits of Reveleer's AI-powered next-generation retrospective risk technology:
AI-Powered clinical review: Clinical insights with up to 99% accuracy, minimizing coding errors and improving RAF capture.
Dynamic HCC validation: Real-time hierarchical dynamic validation improves efficiency without compromising compliance or increasing audit risk.
Seamless collaboration tools: Real-time audit log, annotations, and in-app messaging improve workflow efficiency and coordination.
Enhanced member view: Comprehensive health profiles enable better clinical insights and accurate coding decisions.
Optimized user experience: Dual-screen support, bulk actions, and dark mode enhance productivity and ease the cognitive burden for users.
Powerful Platform: In 2024, we processed 1.1 billion pages of medical charts, and delivered 2.5 million diagnoses.
'Retrospective risk adjustment is critical for financial sustainability in value-based care, yet current technologies and manual processes are fragmented, time-consuming and prone to errors,' said Jay Ackerman, CEO of Reveleer. 'Our next generation risk solution is just the beginning of how Reveleer intends to lead the market into the next evolution of value-based care. The pressure of a changing value-based care ecosystem on our customers is only increasing, and so must our investment in innovation.'
Reveleer will be exhibiting at RISE National, March 11 – 13, 2025 in San Antonio, TX where it will be showcasing this next generation risk solution, along with its quality and clinical intelligence solutions.
To learn more about Reveleer, our platform, and solutions, visit www.reveleer.com.
About Reveleer
As the industry's pioneering value-based care (VBC) enablement platform, Reveleer is purpose-built to solve the most pressing real-world challenges faced by providers and health-plan organizations today. By unifying retrieval, clinical intelligence, risk adjustment, quality improvement, and member management solutions into one intelligent, AI-powered system, Reveleer streamlines fragmented workflows to supercharge productivity, enhance care quality, and optimize performance on high-priority value-based initiatives. To learn more about Reveleer's value-based care platform, visit us at Reveleer.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Associated Press

7 minutes ago

• Associated Press

Libertas Bio, a Formation Bio subsidiary, License of Gusacitinib, a Dual JAK/SYK Inhibitor, to Sanofi

NEW YORK, June 23, 2025 /PRNewswire/ -- Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study. Gusacitinib was acquired by Formation Bio (formerly known as TrialSpark) in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next stage of development, with Sanofi leveraging its global expertise in drug development and commercialization to explore its potential in new indications. This transaction exemplifies Formation Bio's differentiated business model: identifying and acquiring high-potential clinical-stage assets. Formation Bio and Sanofi have several long-standing collaborations focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise. This latest transaction builds on that collaboration, further strengthening both companies' commitment to advancing promising therapies through innovative technology and scientific excellence. Benjamine Liu, Co-Founder & CEO of Formation Bio, commented: 'Formation Bio is redefining drug development through radical efficiency at every step. We acquire high-potential assets, move quickly to unlock value, and partner at key inflection points. We're proud to have Sanofi as a world-class partner working together to accelerate innovation in medicine.' About Formation Bio Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients. For more information, please visit Media Contact: [email protected] View original content to download multimedia: SOURCE Formation Bio

Yahoo

21 hours ago

• Yahoo

Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength

GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies? The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength. Before: AI-Powered Foresight for Accurate Market Opportunity Detection AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning. Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification. AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas. Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit. End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product. During: Efficient Execution to Deliver Outstanding Products Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams. Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays. Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements. Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time. Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste. Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts. AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge. Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response. Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation. Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D. Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis. Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks. After: Data-Driven Innovation Strategy Optimization Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance. Deeper Insights: Identify key factors that influence project success. Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration. Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product. Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation. Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility. The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape. We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster! Website: Email：Marketing@ View original content: SOURCE Cyberway Information Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

a day ago

• Yahoo

Record Full Year 2025 Earnings: EPS Beats Expectations

Revenue: UK£41.6m (down 8.3% from FY 2024). Net income: UK£9.75m (up 5.2% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by lower expenses. EPS: UK£0.05 (up from UK£0.048 in FY 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Looking ahead, revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 2.1% growth forecast for the Capital Markets industry in the United Kingdom. Performance of the British Capital Markets industry. The company's shares are up 9.4% from a week ago. You still need to take note of risks, for example - Record has 2 warning signs we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data